Document is current
Any future updates will be listed below
-
Authors
Wu, Xiaoli S.
He, Xue-Yan https://orcid.org/0000-0001-5423-5997
Ipsaro, Jonathan J. https://orcid.org/0000-0002-2743-3776
Huang, Yu-Han
Preall, Jonathan B.
Ng, David
Shue, Yan Ting
Sage, Julien https://orcid.org/0000-0002-8928-9968
Egeblad, Mikala https://orcid.org/0000-0002-3371-1445
Joshua-Tor, Leemor https://orcid.org/0000-0001-8185-8049
Vakoc, Christopher R. https://orcid.org/0000-0002-1158-7180
- License Information
-
More Information
Article History
Received: 2 October 2021
Accepted: 9 May 2022
First Online: 16 May 2022
Competing interests
: C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer-Ingelheim and Treeline Biosciences; and owns a stock option from Treeline Biosciences. M.E. is a member of the research advisory board for brensocatib for Insmed; a member of the scientific advisory board for Vividion Therapeutics; and a consultant for Protalix. J.S. has received research funding from Abbvie and Pfizer and licensed a patent (11046763 to Stanford University) to Forty Seven/Gilead on the use of CD47-blocking strategies in SCLC.
